Research Laboratory and Hepatic Surgery Center, Department of Hepatic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Front Immunol. 2023 Apr 26;14:1073531. doi: 10.3389/fimmu.2023.1073531. eCollection 2023.
Hepatocellular carcinoma (HCC) is the most common type of liver cancer and has a high mortality rate worldwide. The percentage of HCC patients with vascular invasion at the time of initial HCC diagnosis is 10%-40%. According to most guidelines, HCC with vascular invasion is classified as advanced stage, and resection is only suggested for a minority of such patients. Recently, advances in systemic and locoregional treatments for such patients have resulted in amazing response rates. Therefore, a "conversion therapy" strategy including systemic and locoregional treatments is proposed to select patients from an initially unresectable state to eventually undergo R0 resection. Recently, many studies have proven that conversion therapy followed by subsequent surgery is achievable in well-selected advanced HCC patients and can provide prolonged long-term outcomes. Based on published research, this review has summarized the clinical experience and evidence of conversion treatment in HCC patients with vascular invasion.
肝细胞癌(HCC)是最常见的肝癌类型,全球死亡率很高。在初始 HCC 诊断时,有血管侵犯的 HCC 患者比例为 10%-40%。根据大多数指南,有血管侵犯的 HCC 被归类为晚期,只有少数此类患者适合进行切除术。最近,针对此类患者的全身和局部治疗的进展带来了令人瞩目的反应率。因此,提出了一种“转化治疗”策略,包括全身和局部治疗,旨在将最初无法切除的患者选择为最终接受 R0 切除术的患者。最近,许多研究已经证明,对于精心选择的晚期 HCC 患者,转化治疗后再进行手术是可行的,并且可以提供长期的生存获益。基于已发表的研究,本文综述了血管侵犯的 HCC 患者转化治疗的临床经验和证据。